About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
About us
Introduction
Quality forum
Medicines UK structure
Medicines UK executive team
Our members
Associate members
Disclosure
Our core focus
Patients
Quality
Value
Sustainability
Partnership
Key issues
Introduction
Generic Pricing
Benefits to the NHS
Current supply issues
Patient access
Patient information
Freedom in market pricing
Getting to market
Sustainability
MHRA performance
Better Patent Regulation
Biosimilars
Falsified Medicines Directive
Industry-NHS guidance
About generics
Introduction
Industry overview
The generics industry
Studies on the generic medicines market in the UK
Generics FAQs
News
Current news
Information
Join us
Introduction
Associate Membership
Associate Members
Contact us
Biosimilars
Current news
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2018
07.12.2018
Medicines UK reaction to Government letter on no-deal Brexit preparations
03.12.2018
Reaction to the proposed changes to the statutory scheme to control the costs of branded health service medicines
23.11.2018
New voluntary scheme for Branded Medicines Pricing and Access
12.10.2018
Response to the Public Accounts Committee (PAC) report into price increases in generic medicines
24.09.2018
FMD safety feature consultation response
24.08.2018
No-deal Brexit technical notices and reference products
23.08.2018
Response to government's publication of technical notices on plans to regulate medicines in the event of a no-deal Brexit
23.08.2018
Response to the Secretary of State for Health's letter to medicines Marketing Authorisation Holders
07.08.2018
Reaction to the Government's publication of a consultation on changes to the statutory medicines pricing scheme
31.07.2018
Director General of Medicines UK and British Biosimilars Association (BBA) Warwick Smith's reaction to NHS Improvements study on the savings delivered from 10 medicines which have switched to generics or biosimilars
05.07.2018
Public Accounts Committee on concessionary pricing of generic medicines
21.06.2018
Medicines UK and BBA reaction to draft withdrawal agreement and SPCs
08.06.2018
Medicines UK reaction to the National Audit Office investigation into NHS spending on generic medicines in primary care
01.06.2018
Paul Fleming, technical director of Medicines UK, commented on the Access to Medicines Report.
29.05.2018
Tim de Gavre takes up Medicines UK Chair role
17.05.2018
Business, Energy and Industrial Strategy (BEIS) Committee report on the impact of Brexit on the pharmaceutical sector
26.04.2018
Medicines UK reaction to King's Fund report on medicines spend
24.04.2018
Generic medicines manufacturers urged to signup now to SecurMed UK
23.03.2018
Statement in response to the EU Council ratifying the Brexit transition deal
21.03.2018
Medicines UK reaction to the Health and Social Care Committee's Report on Brexit: medicines, medical devices and substances of human origin
23.02.2018
The Department of Health and Social Care's report and recommendations into Medication and dispensing errors
22.02.2018
National Audit Office
19.01.2018
AMR Industry Alliance Progress press release
19.01.2018
AMR Industry Alliance Progress report
Highlights
25.06.2020
Life Sciences Recovery Roadmap
16.06.2020
Reaction to dexamethasone treatment for Covid-19 patients
02.04.2020
Statement of intent for UK life sciences
25.03.2020
COVID-19 Medicines UK update
20.03.2020
Key worker welcome
18.03.2020
Covid-19 statement
04.03.2020
Response to today's CMA fines on anti-competitive agreements
06.02.2020
Reaction to the Government's document on the UK's approach to trade deals with non-EU nations